Tarsus Pharmaceuticals, Inc. (TARS) — Stock Score Summary

Tarsus Pharmaceuticals, Inc. (TARS) has a MoatMap StockRank of 48/100 based on Quality (47/100), Value (39/100), and Momentum (48/100) factor scores. The current signal is HOLD. Tarsus is an early-stage biopharma company. Despite the potential of its lead product, it lacks the diversified cash flows, high ROIC, and established economic moat required of a Terry Smith-style compounder.

Tarsus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of novel treatments for ophthalmic and dermatologic conditions. The company's competitive moat stems from its innovative product pipeline, particularly its lead product for Demodex blepharitis, addressing a significant unmet medical need with a differentiated therapeutic approach. Tarsus leverages a targeted R&D strategy to develop first-in-class therapies.

Key Financial Metrics

Price$61.55
Market Cap$2.6B
P/E (Forward)21.05
Price/Book7.48
Return on Equity-14.0%
Return on Invested Capital-13.1%
Debt/Equity25.41
Gross Margin80.0%
Operating Margin-3.8%
Revenue Growth106.9%
Free Cash Flow$-21M

Tarsus Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Tarsus Pharmaceuticals, Inc.’s (TARS) StockRank?
MoatMap’s StockRank for Tarsus Pharmaceuticals, Inc. (TARS) is 48/100, with a Hold signal. It is a composite of Quality (47), Value (39), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Tarsus Pharmaceuticals, Inc. have an economic moat?
Tarsus Pharmaceuticals, Inc. (TARS) has a Quality factor score of 47/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tarsus Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Tarsus Pharmaceuticals, Inc. (TARS) is Hold, based on a StockRank of 48/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tarsus Pharmaceuticals, Inc. in?
Tarsus Pharmaceuticals, Inc. (TARS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksTARS deep dive reportAI ChampionsHow we score stocksSense-check another stock